Tokio Marine Asset Management Co. Ltd. Decreases Position in Elanco Animal Health Incorporated (NYSE:ELAN)

Tokio Marine Asset Management Co. Ltd. reduced its stake in shares of Elanco Animal Health Incorporated (NYSE:ELAN) by 4.8% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 29,500 shares of the company’s stock after selling 1,500 shares during the quarter. Tokio Marine Asset Management Co. Ltd.’s holdings in Elanco Animal Health were worth $433,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also recently bought and sold shares of ELAN. Canada Pension Plan Investment Board purchased a new position in Elanco Animal Health in the 2nd quarter valued at about $55,599,000. Magnetar Financial LLC increased its position in shares of Elanco Animal Health by 61.2% during the second quarter. Magnetar Financial LLC now owns 8,336,657 shares of the company’s stock worth $120,298,000 after acquiring an additional 3,164,350 shares during the last quarter. Assenagon Asset Management S.A. lifted its stake in shares of Elanco Animal Health by 363.1% in the third quarter. Assenagon Asset Management S.A. now owns 1,548,506 shares of the company’s stock worth $22,748,000 after acquiring an additional 1,214,123 shares in the last quarter. Great Lakes Advisors LLC purchased a new position in Elanco Animal Health in the second quarter valued at about $16,043,000. Finally, Price T Rowe Associates Inc. MD grew its stake in Elanco Animal Health by 4.0% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 22,139,018 shares of the company’s stock valued at $360,425,000 after purchasing an additional 852,281 shares in the last quarter. 97.48% of the stock is owned by institutional investors and hedge funds.

Elanco Animal Health Stock Down 0.4 %

ELAN stock opened at $13.98 on Friday. The firm has a market cap of $6.91 billion, a price-to-earnings ratio of 34.95, a PEG ratio of 1.48 and a beta of 1.41. Elanco Animal Health Incorporated has a 1-year low of $11.20 and a 1-year high of $18.80. The firm has a fifty day moving average price of $13.82 and a two-hundred day moving average price of $14.76. The company has a debt-to-equity ratio of 0.66, a current ratio of 2.55 and a quick ratio of 1.31.

Elanco Animal Health (NYSE:ELAN) last announced its quarterly earnings data on Thursday, November 7th. The company reported $0.13 earnings per share for the quarter, beating analysts’ consensus estimates of $0.12 by $0.01. Elanco Animal Health had a net margin of 4.60% and a return on equity of 6.78%. The business had revenue of $1.03 billion during the quarter, compared to the consensus estimate of $1.04 billion. During the same quarter in the prior year, the firm earned $0.18 EPS. The company’s revenue for the quarter was down 3.6% compared to the same quarter last year. Research analysts predict that Elanco Animal Health Incorporated will post 0.91 EPS for the current year.

Wall Street Analysts Forecast Growth

ELAN has been the subject of several research analyst reports. Morgan Stanley cut Elanco Animal Health from an “overweight” rating to an “equal weight” rating and reduced their target price for the company from $17.00 to $15.00 in a research note on Thursday, September 19th. Stifel Nicolaus reiterated a “buy” rating and set a $20.00 price objective on shares of Elanco Animal Health in a research note on Thursday, September 19th. Finally, Barclays raised their price objective on shares of Elanco Animal Health from $19.00 to $20.00 and gave the stock an “overweight” rating in a report on Friday, November 8th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat, Elanco Animal Health currently has a consensus rating of “Hold” and a consensus target price of $17.14.

Insider Transactions at Elanco Animal Health

In other news, Director Michael J. Harrington purchased 3,500 shares of Elanco Animal Health stock in a transaction dated Thursday, August 22nd. The stock was bought at an average price of $14.85 per share, with a total value of $51,975.00. Following the completion of the acquisition, the director now owns 81,094 shares in the company, valued at $1,204,245.90. The trade was a 4.51 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.57% of the company’s stock.

Elanco Animal Health Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.